Anyone who's spent an evening researching GLP-1 medications keeps running into the same two names: Mounjaro vs. Wegovy. Weekly injections, both of them. Capable of real, meaningful weight loss. And both come loaded with a price tag and a list of fine prints that makes the decision feel heavier than it should.
They're not interchangeable, though — the differences genuinely matter. Here's what separates them, laid out so a conversation with a doctor can start from an informed place rather than a guess.
The Short Answer
Wegovy contains semaglutide and carries FDA approval specifically for chronic weight management. Mounjaro contains tirzepatide and is FDA-approved for type 2 diabetes — so using it for weight loss alone means a doctor is prescribing it off-label. (It's weight-loss-approved sibling called Zepbound, and yes, it's the same active ingredient under a different name.)
That single distinction ends up mattering a lot, especially for insurance. But approval status is just the first difference, not the only one.
How They Work in the Body
Both medications act on GLP-1, a hormone the gut releases after eating. It slows digestion, curbs appetite, and signals the brain that the stomach is full — which is why both drugs tend to produce steady, gradual weight loss rather than anything dramatic overnight.
Mounjaro goes one step further. It also activates GIP; a second gut hormone tied to insulin release and fat metabolism. Two hormones instead of one is the main reason tirzepatide tends to edge out semaglutide in head-to-head comparisons; it's working the appetite system from two angles at once rather than just one.
Which One Leads to More Weight Loss?
This is usually the first question on anyone's mind, and the research leans in a fairly consistent direction. A head-to-head trial published in the New England Journal of Medicine found that people on tirzepatide lost around 20% of their body weight, versus roughly 14% for those on semaglutide. Other trials tell a similar story — tirzepatide at its highest dose has pushed past 20% of starting weight, while semaglutide's highest dose has landed anywhere from 15% to 21%, depending on the study and the exact dosing schedule used.
None of that makes Wegovy a weaker option. It's still one of the most effective weight-loss medications available. What the numbers show is more modest: tirzepatide's dual mechanism gives it a statistical edge in most comparisons to run so far — not a knockout, just an edge.
Dosing and How Each One Is Taken
Wegovy starts small — 0.25 mg weekly — and climbs over several months toward a maintenance dose as high as 7.2 mg (a higher-dose version; Wegovy HD, now exists for patients who need an extra push). Mounjaro starts at 2.5 mg weekly and climbs toward a maximum of 15 mg.
Both follow the same slow-and-steady philosophy, typically adjusting every four weeks based on how well the body tolerates it. Neither is a "start high" drug. That gradual ramp-up exists for a reason: it keeps nausea and other digestive side effects manageable instead of overwhelming.
Side Effects: What to Expect
The side effect profiles overlap heavily, which makes sense given how similar the mechanisms are. Nausea, vomiting, and diarrhea are common with both, especially during the early dose-increase months. Constipation and fatigue show up frequently, too.
Further down the list are the more serious, less common risks: pancreatitis, gallbladder problems, and a boxed FDA warning about thyroid tumors observed in animal studies. Whether that risk translates to humans is still unclear, but out of caution, doctors generally steer clear of prescribing either drug to patients with a personal or family history of certain thyroid cancers.
Neither medication is "safer" in some blanket sense. Personal health history should drive that decision — not a general side-effect list, and not which drug happened to trend online first.
Cost and Insurance: Often the Real Deciding Factor
This is where Mounjaro's diabetes-only approval turns into a practical headache. Because Wegovy carries approval specifically for weight loss, insurers are somewhat more inclined to cover it for that purpose — though coverage still hinges on the specific plan and usually requires hitting certain BMI or comorbidity thresholds. Mounjaro prescribed off label for weight loss, has a rockier path to coverage unless type 2 diabetes is also part of the picture.
Without insurance, both medications tend to run close to four figures a month. Worth a call to the insurance provider before committing either one — it can change the math entirely.
So, Which One Wins?
There's no universal answer — only a better fit depending on the situation. Mounjaro tends to make more sense when the goal is the strongest average weight-loss results current studies can offer, when type 2 diabetes is already part of the diagnosis (which tends to smooth out insurance approval), or when a doctor sees the dual-hormone mechanism as the better metabolic fit.
Wegovy tends to make more sense for anyone specifically seeking a medication approved for weight loss rather than prescribed off label, anyone dealing with cardiovascular risk factors or a related liver condition covered under Wegovy's expanded approvals, or anyone for whom insurance coverage tied to weight management specifically is the deciding factor.
The Bottom Line
Both drugs can produce real, sustained weight loss when paired with changes to diet and activity — but they're not the same medication wearing two different labels. The right pick comes down to medical history, insurance realities, and how a given body responds to each mechanism.
Choosing based on which drug "won" in a clinical trial misses the point. The smarter move is a conversation with a healthcare provider who can look at labs, history, and goals — and help figure out which medication fits the bigger picture. For anyone without a provider who prescribes GLP-1 medications already, a telehealth weight-management clinic or a primary care doctor is the natural place to start.
